Table 1 Patient characteristics

From: Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial

Patient Characteristics

Demographics

 Age, mean±s.d.

57.8 ± 12.7

Sex, n (%)

 Male

41 (68)

 Female

19 (32)

 KPS, mean ± s.d.

90 ± 8.1

Steroid use at registration

 Patient receiving steroids (n)

28/60

 Daily dosage, mg/day (range)

0-8

MGMT status, n (%)

 Methylated

18 (30%)

 Unmethylated

33 (55%)

 Indeterminate

7 (12%)

 Unknown

2 (3%)

IDH status, n (%)

 WT

56 (93%)

 Mutant

4 (7%)